Clinical trials
Vaccination; Infection clinical trials
Below are recruiting vaccination; infection clinical trials, each written for real people, not researchers. We’re tracking 93 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06514547RecruitingPhase 4
Vaccine response and aging in people with HIV
This study is for people living with HIV who are 18 or older and on HIV medication. Researchers want to learn how the immune system and vaccine response change as people age, and will give a pneumococcal (pneumonia) vaccine to study that.
Minneapolis, MinnesotaAges 18 years+ - NCT06168032Recruiting
COVID-19 vaccine for lung cancer patients
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
BeijingAges 18 years+ - NCT07407569RecruitingPhase 2
HPV vaccine study for women with HPV16
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
Antwerp, WilrijkAges 18–45 - NCT05197621Recruiting
Study how COVID-19 affects pregnancy and newborn outcomes
This study looks at how COVID-19 and COVID vaccination during pregnancy may affect mothers and newborns. Your team will collect health information around delivery to understand what outcomes are most common.
Baltimore, MarylandAges 14–55 - NCT05973084Recruiting
COVID spread study in Malawi households and vaccine recipients
This study tracks how COVID-19 spreads and causes illness in real households in Blantyre, Malawi, and compares groups after infection or vaccination. If you qualify, you’ll do follow-up testing and visits for several months.
Boston, MassachusettsAges 5–75 - NCT06306196RecruitingPhase 2
Hepatitis E vaccine study in healthy adults, children, and people with HIV
This study tests a hepatitis E vaccine called Hecolin in healthy people (ages 2–45) and in adults (18–45) living with HIV who are on antiviral treatment. It aims to see how well the vaccine works and if it's safe for different groups.
Ga-RankuwaAges 2–45 - NCT07582796RecruitingPhase 1/Phase 2
RSV Vaccine Study for Adults in China
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
Zigong, SichuanAges 18 years+ - NCT04910802RecruitingPhase 4
HPV vaccine with routine HPV screening for ages 22–26
This study looks at giving the HPV vaccine (Gardasil 9) to women while they go through Sweden’s routine HPV screening. It helps researchers understand how vaccine use alongside screening affects HPV infection and cervical cancer prevention.
StockholmAges 22–27 - NCT05808166RecruitingPhase 2
Hepatitis E vaccine test in healthy pregnant women
This Phase 2 study tests the safety of Hecolin® (a hepatitis E vaccine) and how well it helps the body build protection in healthy pregnant women. You might be invited if you’re pregnant during specific weeks and healthy enough for vaccination and follow-up blood tests.
Karachi, SindhAges 16–45 - NCT06805656RecruitingPhase 2
Trial to reduce HIV reservoirs aiming for treatment-free remission
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
São Paulo, São PauloAges 18–65 - NCT05947890RecruitingPhase 2
Testing an immune-boosting TB vaccine in people with or without HIV
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
Johannesburg, GautengAges 12–55 - NCT06597916RecruitingPhase 2
RSV vaccine study for people with weakened immune systems
This study tests how well an RSV vaccine (Arexvy) works in people whose immune systems are weakened by certain cancers, autoimmune diseases, or treatments. It aims to see if the vaccine can protect these vulnerable groups from respiratory infections.
ViennaAges 18 years+ - NCT07195032RecruitingPhase 4
MMR vaccine safety in kids after heart transplant
This trial tests whether the MMR (measles, mumps, rubella) vaccine is safe and works well for children who have had a heart transplant. It may help protect you from these diseases if you haven't had the vaccine or no longer have immunity.
Kansas City, MissouriAges 1–17 - NCT05672927RecruitingPhase 4
Comparing HPV vaccine schedules: 2 doses vs 3 doses
This study compares how well your immune system responds to an HPV vaccine given as either 2 doses or 3 doses in people ages 27–45 who have never had the HPV vaccine. It may help improve HPV prevention strategies and guide the best dose schedule for adults.
Galveston, TexasAges 27–45 - NCT04299724RecruitingPhase 1
COVID-19 Vaccine Safety and Immune Response Study
This early-stage trial tests a new COVID-19 vaccine designed to teach your immune system to fight the virus. It is for people who have just tested positive for COVID-19 and are otherwise healthy.
Shenzhen, GuangdongAges 6 months–80 years - NCT04588402Recruiting
Tests whether HPV vaccination prevents cervical HPV infection in young women
This study looks at whether HPV vaccination lowers the chance of getting HPV in the cervix. It will collect cervical samples and ask questions to see how vaccination affects infection in women in Sikkim, India.
Gangtok, SikkimAges 18–22 - NCT07663032RecruitingPhase 1
Pan-Salmonella vaccine study for healthy young adults
This trial tests an experimental vaccine designed to protect against multiple types of Salmonella bacteria (which cause typhoid fever and other infections). It is given to healthy adults aged 18 to 45 to check safety and immune response.
BloemfonteinAges 18–45 - NCT07094711RecruitingPhase 2
BCG vaccine boost for MAC lung disease
This study tests whether a single dose of the BCG vaccine (a live vaccine used for TB) can help the immune system fight MAC lung disease. Participants must not be on MAC treatment now, but may start it during the study if needed.
Charlottesville, VirginiaAges 18 years+ - NCT06598475Recruiting
Improving HPV vaccination in Latino teens at health centers
This trial tests a program to help community health centers recommend and boost HPV vaccination rates among Latino adolescents aged 11-12. It aims to support health care providers and staff with education and resources.
Houston, TexasAges 11–17 - NCT06381739RecruitingPhase 2
New inhaled COVID-19 booster vaccine trial
This trial tests a next-generation COVID-19 vaccine given as an inhaled mist. It is for adults who have already had at least 3 doses of an mRNA COVID vaccine and are looking for a potentially stronger or longer-lasting immune response.
Halifax, Nova ScotiaAges 18–65 - NCT07300267RecruitingPhase 1
Study of a new pneumococcal vaccine for infants and toddlers
This trial tests a new vaccine called V118C to protect children against pneumococcal disease. It is for two age groups: toddlers aged 12-15 months who already had 3 doses of a standard pneumococcal vaccine, and babies about 2 months old who have not had any pneumococcal vaccine yet.
Madera, CaliforniaAges 2 months–1.3 years - NCT06908096RecruitingPhase 1
EBV nanoparticle vaccine study for healthy adults
This study tests two experimental vaccines against Epstein-Barr virus (EBV), the germ that causes mono. You may be able to join if you are a healthy adult aged 18–29 and haven't had an EBV vaccine before. The trial will check if the vaccines are safe and trigger an immune response.
Bethesda, MarylandAges 18–29 - NCT05334706RecruitingPhase 4
Vaccine study to lower HPV spread in HPV-positive women
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
L'Hospitalet de Llobregat, CataloniaAges 18 years+ - NCT07379580RecruitingPhase 2
Test of an mRNA vaccine for mpox in Africa
This trial tests a new mRNA vaccine to prevent mpox. It looks at how safe and effective the vaccine is in adults who have or haven't been exposed to mpox or similar viruses before.
KinshasaAges 18–64
Hear when a new Vaccination; Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for vaccination; infection?
- Yes. Clin2 currently lists 93 recruiting vaccination; infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a vaccination; infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a vaccination; infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.